Ubrelvy is expensive because it’s a brand-name drug in a new class of migraine treatments with no generic alternative and limited competition. A single dose costs roughly $100 or more at retail, and a year of treatment for someone with frequent migraines can run over $70,000 at wholesale pricing. That price reflects a combination of patent protection, the cost of developing a novel drug mechanism, and a market where only two or three competitors exist.
What Makes Ubrelvy Different From Older Options
Ubrelvy (ubrogepant) belongs to a class of drugs called gepants, which work by blocking a specific protein involved in migraine pain called CGRP. During a migraine, CGRP levels surge and trigger inflammation and pain signaling. Ubrelvy latches onto the CGRP receptor with extremely high precision, stopping that cascade. It’s taken as a pill, which sounds simple, but developing a small molecule that could block this receptor effectively while being absorbed through the gut took years of research.
Older migraine medications like sumatriptan (a triptan) work through a completely different pathway, constricting blood vessels and affecting serotonin receptors. Triptans have been available as generics for years and cost a fraction of what Ubrelvy does. But they also come with limitations: they’re not safe for people with cardiovascular disease, and a significant number of migraine patients either don’t respond to them or can’t tolerate the side effects. Ubrelvy was designed specifically to fill that gap, and drugs that serve unmet medical needs tend to carry premium prices.
The Cost of Getting to Market
Ubrelvy’s FDA approval in December 2019 was backed by two large, randomized, placebo-controlled clinical trials (called ACHIEVE I and ACHIEVE II), plus an open-label extension study that followed 813 patients for up to a year. These trials tested both the 50 mg and 100 mg doses against placebo in adults during active migraine attacks. Running trials of this size, with the regulatory rigor the FDA requires for a first-in-class oral treatment, costs hundreds of millions of dollars. The drug was originally developed by Allergan, which was later acquired by AbbVie, so the investment spans two major pharmaceutical companies.
None of those development costs are publicly itemized, but the pricing math is straightforward: the manufacturer needs to recoup its investment during the years of patent exclusivity before generics can enter the market. With a relatively narrow patient population (people with migraine who need something beyond triptans), the per-dose price has to be high enough to cover that investment across fewer prescriptions than, say, a blood pressure medication taken daily by millions.
How Ubrelvy Compares to Competitors
Ubrelvy isn’t the only gepant on the market, but the competition is thin. Nurtec ODT (rimegepant) is its closest rival, and it’s priced in the same range. A cost-effectiveness analysis published in The American Journal of Managed Care calculated annual costs assuming about 4.3 migraine attacks per month (52 attacks per year). At adjusted wholesale pricing, Ubrelvy came to approximately $74,800 per year, Nurtec ODT around $79,500, and a newer nasal spray option (zavegepant) about $92,200. By comparison, usual care with a mix of over-the-counter pain relievers and generic sumatriptan ran about $53,800 annually under the same assumptions.
Those annual figures are based on frequent use and wholesale pricing, so they won’t match what most individuals pay out of pocket. But they illustrate the core issue: when only two or three brand-name drugs compete in a category, there’s no downward pressure on pricing. Generic triptans cost a few dollars per dose. Gepants cost 20 to 50 times more, and will continue to until patents expire or more competitors arrive.
Insurance Often Creates Extra Hurdles
Even with insurance, Ubrelvy frequently lands on higher formulary tiers, meaning larger copays. Many insurers also require prior authorization or step therapy before they’ll cover it. Step therapy means you have to try and fail cheaper medications first, typically two different triptans at effective doses, before the insurer will approve a gepant.
The VA system offers a clear example of how restrictive access criteria can be. To qualify for Ubrelvy through the VA, a patient needs a confirmed migraine diagnosis, moderate to severe attacks, a prescription initiated by a neurologist or headache specialist, documented failure of or intolerance to two different triptans, and current use of preventive migraine therapy if indicated. Private insurers often impose similar requirements, though the specifics vary by plan. The result is that many patients face weeks or months of appeals and paperwork before coverage kicks in, and some are denied altogether.
Ways to Reduce Your Out-of-Pocket Cost
AbbVie, the company that sells Ubrelvy, offers a savings card for commercially insured patients that can significantly reduce copays. The specific terms change periodically, but these cards typically bring the per-prescription cost down to $10 or less for eligible patients. The catch: savings cards generally don’t work with government insurance programs like Medicare, Medicaid, or Tricare.
For uninsured or underinsured patients, AbbVie runs a patient assistance program called myAbbVie Assist. Eligibility is income-based, with thresholds that are relatively generous. A single person earning $63,840 or less per year qualifies, as does a household of two earning $86,560 or less, a household of three at $109,280, or a household of four at $132,000. Each additional family member adds about $22,720 to the threshold. If you qualify, the program provides the medication at no cost. One important exclusion: patients whose commercial insurance plans require them to apply to the assistance program as a condition of coverage (sometimes called alternate funding programs) are not eligible.
Will Ubrelvy Get Cheaper?
The price of Ubrelvy is unlikely to drop significantly while it remains under patent protection. AbbVie holds exclusivity, and no generic version of ubrogepant is currently available. When the patent eventually expires, generic manufacturers can produce the drug at a fraction of the cost, as happened with triptans. Until then, the combination of patent exclusivity, a small competitive field, and the high fixed costs of pharmaceutical development will keep the price where it is.
If you’re paying more than you can afford, the manufacturer savings card and patient assistance program are the most direct routes to lower costs. Your prescriber’s office can also sometimes provide samples or help navigate insurance appeals. Some patients find that switching to Nurtec ODT, which is priced similarly but may sit on a different formulary tier with your specific insurer, results in better coverage.